Intra Cellular Therapies reported $31.84M in Gross Profit on Sales for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Acadia Pharmaceuticals ACAD:US $ 112.52M 15.68M
ALKERMES ALKS:US 223.39M 47.4M
Biocryst Pharmaceuticals BCRX:US $ 49.68M 2.95M
Biogen BIIB:US $ 1777.9M 295.8M
Bristol Myers Squibb BMY:US $ 9177M 452M
Esperion Therapeutics ESPR:US $ 11.71M 1.38M
Gilead Sciences GILD:US $ 5166M 549M
Halozyme Therapeutics HALO:US $ 101.36M 20.94M
Intra Cellular Therapies ITCI:US $ 31.84M 8.71M
JAZZ PHA JAZZ:US $ 698.44M 62.14M
Johnson & Johnson JNJ:US $ 15828M 1021M
Marinus Pharmaceuticals MRNS:US 13.02M 11.5M
Nektar Therapeutics NKTR:US $ 19.51M 0.66M
Neurocrine Biosciences NBIX:US $ 306M 1.9M
Novartis NVS:US $ 9059M 463M
Supernus Pharmaceuticals SUPN:US $ 134.57M 7.48M
United Therapeutics UTHR:US $ 436M 55.4M
Vanda Pharmaceuticals VNDA:US $ 54.53M 7.26M